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The lack of an adequate scale-down model for the cell culture stages of legacy processes is an ongoing issue
across the industry. This presentation will describe an existing scale-down model, the modifications made to it,
and an example of the utility of the new model. The scale-down model for Process X was originally developed
based on power per unit volume, with minimal modification to accommodate other input parameters. This scaledown model performed significantly differently from the manufacturing-scale process with respect to cell growth,
metabolites, and productivity. For example, the productivity in the scale-down model was 3 to 4 times higher than
at the manufacturing scale, and the peak viable cell density (PVCD) for the scale-down model was two times the
PVCD of the manufacturing scale, while cell viability was also consistently higher in the scale-down model. There
was a clear need to develop a scale-down model that takes into account additional scaling parameters and better
mimics manufacturing scale to increase understanding of the manufacturing-scale process. Analysis of mixing
and sparging parameters indicates that the manufacturing scale results differed significantly from the model. The
scale-down model was therefore modified to reduce air flow rates, increase the total volume, and to over-sparge
air early in the process to better mimic the manufacturing-scale behavior and trends. These changes resulted in
a scale-down model which closely matches the large-scale growth, viability, and metabolite profiles. This scaledown model has been used to successfully screen raw materials which are known to impact the manufacturingscale process. This improved scale-down model will enable process improvement studies, effective satellite runs,
improve understanding of manufacturing-scale results, address deviations, and will help ensure robust production.

